EPICOVIDEHA

To assess the epidemiology and outcomes of patients with HM infected of COVID-19

disease

• To estimate the incidence and type of COVID-19 disease (i.e. symptomatic, asymptomatic).
• To evaluate admission to ICU.
• To estimate the frequency of pre-existing co-morbidities.
• To evaluate acute mortality rate (within 30 days from diagnosis of COVID-19).
• To estimate the rate of overall case-fatality rate.
• To assess the spatial-geographical patterns of disease.
• To stratify patients per off-therapy/on-therapy, per type of therapy (chemo,
  
  immunotherapy, cell therapy, stem cell transplant)

• Age equal to or greater than 18 years of age.
• History of hematological malignancies (acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas, myeloma, chronic myeloprolipherative disorders) at any stage/status.
• Active hematological malignancies at any stage/status.
• Diagnosis of hematological malignancy (acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas, myeloma, chronic myeloprolipherative disorders) at any stage/status.
• SARS-CoV-2 positive test (nasopharyngeal, BAL, fecal), documented by Real-Time Reverse Transcriptase (RT)-PCR Diagnostic Panels.

• Hematological diseases, other than hematological malignancies.
• Not tested positive for SARS-CoV-2
• Patients “off therapy” for more than 5 years